Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 7 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| PEPLIN INC | 227,819 | reported | 14 Jan 2009 | tx 4+226,500 |
| Somaxon Pharmaceuticals, Inc. | 122,287 | reported | 02 Jul 2012 | tx 15+260,783−65,163 |
| Annexon, Inc. | 55,000 | reported | 05 Jun 2025 | tx 5+157,000 |
| Jasper Therapeutics, Inc. | 41,000 | reported | 22 Sept 2025 | tx 10+257,000 |
| TERCICA INC | 11,250 | reported | 06 Jun 2006 | tx 2+11,340 |
| SANGAMO THERAPEUTICS, INC | 10,000 | reported | 01 Jun 2011 | tx 4+30,000−50,000 |
| CONNETICS CORP | 0 | reported | 29 Dec 2006 | tx 81+324,261−1,403,546 |
| Dermira, Inc. | 0 | reported | 20 Feb 2020 | tx 140+1,660,402−2,421,674 |
| Forma Therapeutics Holdings, Inc., | 0 | reported | 14 Oct 2022 | tx 9+47,375−47,375 |
| FS Development Corp. II | 0 | reported | 31 Aug 2023 | tx 10+2,047,500−2,047,500 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 22 Sept 2025 | PURCHASE | Jasper Therapeutics, Inc. | 41,000 | 2.43 USD | |
| 22 Sept 2025 | PURCHASE | Jasper Therapeutics, Inc. | 41,000 | — | derivfirst after silence |
| 03 Jul 2025 | GRANT_AWARD | Jasper Therapeutics, Inc. | 7,500 | 0.00 USD | deriv |
| 05 Jun 2025 | GRANT_AWARD | Annexon, Inc. | 55,000 | 0.00 USD | deriv |
| 06 Jun 2024 | GRANT_AWARD | Jasper Therapeutics, Inc. | 7,500 | 0.00 USD | deriv |
| 05 Jun 2024 | GRANT_AWARD | Annexon, Inc. | 44,000 | 0.00 USD | deriv |
| 22 Mar 2024 | OTHER | CymaBay Therapeutics, Inc. | 80,000 | — | deriv |
| 22 Mar 2024 | OTHER | CymaBay Therapeutics, Inc. | 67,000 | — | deriv |
| 22 Mar 2024 | OTHER | CymaBay Therapeutics, Inc. | 25,000 | — | deriv |
| 22 Mar 2024 | OTHER | CymaBay Therapeutics, Inc. | 14,010 | — | deriv |
| 24 Jan 2024 | GRANT_AWARD | CymaBay Therapeutics, Inc. | 14,010 | 0.00 USD | deriv |
| 28 Nov 2023 | PURCHASE | Jasper Therapeutics, Inc. | 10,000 | 0.65 USD | |
| 21 Nov 2023 | PURCHASE | Jasper Therapeutics, Inc. | 10,000 | 0.64 USD | |
| 17 Nov 2023 | PURCHASE | Jasper Therapeutics, Inc. | 10,000 | 0.60 USD | |
| 20 Nov 2023 | PURCHASE | Jasper Therapeutics, Inc. | 10,000 | 0.63 USD | |
| 16 Nov 2023 | PURCHASE | Jasper Therapeutics, Inc. | 10,000 | 0.60 USD | |
| 01 Nov 2023 | GRANT_AWARD | Jasper Therapeutics, Inc. | 110,000 | 0.00 USD | deriv |
| 31 Aug 2023 | TENDER | FS Development Corp. II | 50,000 | — | |
| 31 Aug 2023 | OTHER | FS Development Corp. II | 562,500 | — | deriv |
| 31 Aug 2023 | OTHER | FS Development Corp. II | 450,000 | — | deriv |
| 31 Aug 2023 | OTHER | FS Development Corp. II | 985,000 | — | deriv |
| 08 Jun 2023 | GRANT_AWARD | Annexon, Inc. | 24,000 | 0.00 USD | deriv |
| 01 Feb 2023 | GRANT_AWARD | FS Development Corp. II | 562,500 | 0.00 USD | deriv |
| 25 Jan 2023 | GRANT_AWARD | CymaBay Therapeutics, Inc. | 25,000 | 0.00 USD | deriv |
| 05 Dec 2022 | PURCHASE | FS Development Corp. II | 12,500 | 1.09 USD |
6 purchases reported after at least 12 months of silence — most recent on 22 Sept 2025.